Abstract
Rivaroxaban is one of most common used DOACs in the treatment of VTE. Rivaroxaban has been tested in a series of premarketing studies and after it has been used in non-interventional studies and in real life studies.All studies experienced that rivaroxaban shows relevant safety concerning main outcomes of VTE therapy as recurrent VTE and major bleedings, in particular in patients that show similar clinical characteristics to those selected for EINSTEIN studies. Suggested doses of rivaroxaban seem to be safe also in real life studies while non-conventional doses may be associated to increased rate of clinical complications as recurrent VTE and major bleedings. Rivaroxaban shows also good safety when used in real life studies in patients with clinical characteristics that differ from those of patients in the EINSTEIN studies.
Highlights
Open AccessWhat We are Learning from Real World Data on Rivaroxaban for the Treatment of Venous thromboembolism (VTE): An Overview
Venous thromboembolism (VTE) is a life-threatening disease that usually may appear as deep vein thrombosis (DVT) and\or pulmonary embolism (PE) [1]
Results testified that the rate of major bleeding was similar in both groups (0.5% in both groups) while a light improvement in prevention of recurrent VTE was available in the group treated with rivaroxaban compared to conventional therapy (1.2% vs. 2-1% respectively) [12]
Summary
What We are Learning from Real World Data on Rivaroxaban for the Treatment of VTE: An Overview. Pierpaolo Di Micco1*, Francesco Dentali, Nicola Mumoli, Matteo Giorgi Pierfranceschi, Maria Amitrano, Fulvio Pomero, Giorgio Vescovo, Gualberto Gussoni, Daniela Mastroiacovo and Andrea Fontanella
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
